Eli Lilly has ended two phase 2 studies of naperiglipron, one in type 2 diabetes and one in healthy adults, citing “strategic business reasons.” A separate trial in 275 adults with obesity or overweight is still underway, with results expected in 2026.

The decision reflects a shift in strategy that aligns with the broader GLP-1 market where obesity drugs have drawn the most attention and revenue potential. While Lilly appears to be stepping back from pursuing type 2 diabetes with this candidate, the company continues to explore its role in obesity treatment.

Until results from the ongoing study are available, the actual viability of naperiglipron remains uncertain.

Sources

Lilly ends 2 of 3 midstage trials for oral GLP-1 contender naperiglipron
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
A Study of LY3549492 in Healthy Weight Adult Participants